Contemporary Trends in the Use of and Expenditures on Digoxin in the United States

Background Digoxin is indicated for the management of heart failure with reduced ejection fraction and atrial fibrillation. Despite stronger guideline recommendations for other pharmacologic and device therapies, digoxin retains a role in select patients unable to tolerate or refractory to standard therapies. Contemporary utilization of and costs related to digoxin in the United States of America (USA) remain uncharacterized. The objective of this study was to estimate trends in digoxin use and expenditures across the USA from 2010 to 2017. Methods We utilized the Medical Expenditure Panel Survey to estimate trends in digoxin use and expenditures across the USA from 2010 to 2017. The Medical Expenditure Panel Survey is an overlapping panel survey that interviews households in the USA to ascertain their healthcare utilization and expenditures. Complex sampling procedures allow for nationally representative estimates of utilization and expenditures. We report the number of digoxin users and expenditures across key subgroups in 2-year increments from 2010 to 2017. Results The number of digoxin users in the USA declined by 47% from 766 users per 100,000 adults in 2010–11 to 402 users per 100,000 adults in 2016–17. While digoxin use declined among women and self-identified White adults, adults living at or below the federal poverty level and those who self-identified as Asian or Hispanic represent an increasing proportion of overall digoxin users. While nationwide digoxin expenditures declined by 26% from 2010–11 to 2012–13, they peaked at $260.3 million in 2014–15 and remained elevated at $188.7 million in 2016–17. Conclusions Despite a nationwide trend towards declining use, digoxin remains prevalent amongst people of Asian and Hispanic descent in the USA. After a spike in cost in 2013, digoxin prices have yet to return to pre-spike levels. The role of digoxin in contemporary heart failure and arrhythmia management will continue to evolve as additional randomized and observational analyses become available..

Medienart:	E-Artikel

Erscheinungsjahr:	2022
Erschienen:	2022

Enthalten in:	Zur Gesamtaufnahme - volume:22
Enthalten in:	American journal of cardiovascular drugs - 22(2022), 5 vom: 24. Juni, Seite 567-575

Sprache:	Englisch

Beteiligte Personen:	Alahmed, Abdullah A. [VerfasserIn] Lauffenburger, Julie C. [VerfasserIn] Vaduganathan, Muthiah [VerfasserIn] Aldemerdash, Ahmed [VerfasserIn] Ting, Clara [VerfasserIn] Fatani, Nayyra [VerfasserIn] Fanikos, John [VerfasserIn] Buckley, Leo F. [VerfasserIn]

Links:	Volltext [lizenzpflichtig]

Anmerkungen:	© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022

doi:	10.1007/s40256-022-00540-x

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	OLC2132007691